Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/2015

01-10-2015 | Original Article

Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer

Authors: G. Quintero-Aldana, M. Jorge, C. Grande, M. Salgado, E. Gallardo, S. Varela, C. López, M. J. Villanueva, A. Fernández, E. Alvarez, P. González, J. Castellanos, J. Casal, R. López, B. Campos Balea

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2015

Login to get access

Abstract

Purpose

Previous studies have shown that docetaxel and cisplatin, as single agents, are effective and relatively well tolerated in patients with advanced gastric cancer. The aim of this study was to assess efficacy and toxicity of a biweekly regimen of docetaxel plus cisplatin in patients with advanced gastric cancer.

Patients/methods

Fifty-five patients with histologically proven advanced gastric cancer with at least 1 measurable lesion and ECOG PS ≤ 2 were enrolled. Patients received docetaxel 50 mg/m2 and cisplatin 50 mg/m2 every 2 weeks until progression disease, unbearable toxicity or a maximum of 12 cycles.

Results

In total, 426 cycles were administered (median 8.5 cycles) to 52 evaluable patients. One patient (1.9 %) showed a complete response, while 21 (40.4 %) had partial responses. The objective response rate was 42.3 % (95 % CI 28.9–55.7), the median time to progression was 5.5 months (95 % CI 4.0–7.0), and the median overall survival was 8.9 months (95 % CI 6.0–11.9). The most common grade 3–4 toxicities per cycle were haematological [neutropenia (5.9 %)].

Conclusions

Biweekly administration of docetaxel and cisplatin in advanced gastric cancer has a manageable toxicity profile and shows a promising antitumour activity as a first-line therapy.
Literature
1.
Garcia M, Jemal A, Ward EM et al (2007) Global cancer facts and figures 2007. American Cancer Society, Atlanta
2.
Wagner AD, Unverzagt S, Grothe W et al (2010) Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 3:CD004064PubMed
3.
Power DG, Kelsen DP, Shah MA (2010) Advanced gastric cancer—slow but steady progress. Cancer Treat Rev 36(5):384–392CrossRefPubMed
4.
Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 3:215–221CrossRef
5.
Cunningham D, Starling N, Rao S et al (2008) Upper gastrointestinal clinical studies group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358(1):36–46CrossRefPubMed
6.
Ross P, Nicolson M, Cunningham D et al (2002) Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20:1996–2004CrossRefPubMed
7.
Webb A, Cunningham D, Scarffe JH et al (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261–267CrossRefPubMed
8.
Yun J, Lee J, Park SH et al (2010) A randomised phase 2 study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer. Eur J Cancer 46(5):885–891CrossRefPubMed
9.
10.
Kim T, Choi SJ, Ahn JH et al (2001) A prospective randomised Phase 3 trial of 5-fluorouracil and cisplatin versus epirubicin, cisplatin and 5FU in the treatment of patients with previously untreated advanced gastric cancer. Eur J Cancer 37(Suppl. 6):1160a
11.
Bleiberg H, Sargent DJ (2011) GASTRIC meta-analyses of 22 randomized trials assessing the influence of chemotherapy in advanced/recurrent gastric cancer. J Clin Oncol 29 (Abstract 4109)
12.
Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) V325 study group. Phase 3 study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24(31):4991–4997CrossRefPubMed
13.
Park YS, Lee J, Kang JH et al (2007) Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer. Cancer Chemother Pharmacol 59(1):17–21CrossRefPubMed
14.
Al-Batran SE, Hartmann JT, Hofheinz R et al (2008) Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 19(11):1882–1887CrossRefPubMed
15.
Shah MA, Stoller R, Shibata S et al (2010) Random assignment multicenter phase 2 study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE). Presented at: Gastrointestinal Cancers Symposium 170a. Orlando, FL, USA, 22–24
16.
Tebbutt NC, Cummins MM, Sourjina T et al (2010) Randomised, non-comparative Phase 2 study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer 102(3):475–481PubMedCentralCrossRefPubMed
17.
Pronk L, Schellens J, Planting A et al (1997) Phase I and pharmacologic study of decetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol 15(3):1071–1079PubMed
18.
Maeda Shingo, Sugiura T et al (2004) Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism. Cancer Sci 8:679–684CrossRef
19.
Roth AD, Maibach R, Martinelli G et al (2000) Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 11:301–306CrossRefPubMed
20.
Schull B, Kornek G, Schmid K et al (2003) Effective combination chemotherapy with bimonthly docetaxel and cisplatin with or without hematopoietic growth factor support in patients with advanced grastroesophageal cancer. Oncology 65:211–217CrossRefPubMed
21.
Ridwelski K, Gebauer T, Fahlke J et al (2001) Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 12:47–51CrossRefPubMed
22.
Ajani JA, Fodor M, Van Cutsem E et al (2000) Multinational randomized phase II trial of docetaxel (T) and cisplatin (C) with or without 5-fluorouracil (FU) in patients (pts) with advanced gastric or GE junction adenocarcinoma (AGC-AGEJC). Proc Am Soc Clin Oncol 19:247a
23.
Page DL, Flemming ID, Fritz AG et al (2002) The AJCC cancer staging manual, 6th edn. Springer, New York
24.
Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E (2005) Phase II multiinstitutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 23:5660–5667CrossRefPubMed
25.
Roth AD, Fazio N, Stupp R et al (2007) Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 25:3217–3223CrossRefPubMed
26.
Cocconi G, Carlini P, Gamboni A et al (2003) Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann Oncol 14(8):1258–1263CrossRefPubMed
27.
Cullinan SA, Moertel CG, Wieand HS et al (1994) Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J Clin Oncol 12:412–416PubMed
28.
Cascinu S, Labianca R, Alessandroni P et al (1997) Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol 15:3313–3319PubMed
29.
Di Lauro L, Belli F, Arena MG et al (2005) Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer. Ann Oncol 16(9):1498–1502CrossRefPubMed
30.
Nitti D, Wils J, Dos Santos JG et al (2006) Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Ann Oncol 17(2):262–269CrossRefPubMed
31.
Popov IP, Jelić SB, Krivokapić ZV et al (2008) Bimonthly 24 h infusion of high-dose 5-fluorouracil vs EAP regimen in patients with advanced gastric cancer. A randomized phase II study. Med Oncol 25(1):73–80CrossRefPubMed
Metadata
Title
Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer
Authors
G. Quintero-Aldana
M. Jorge
C. Grande
M. Salgado
E. Gallardo
S. Varela
C. López
M. J. Villanueva
A. Fernández
E. Alvarez
P. González
J. Castellanos
J. Casal
R. López
B. Campos Balea
Publication date
01-10-2015
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2015
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-015-2839-z

Other articles of this Issue 4/2015

Cancer Chemotherapy and Pharmacology 4/2015 Go to the issue

Original Article

Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug–drug interaction

Original Article

First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations

Original Article

Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration

Review Article

Current controversies in the management of metastatic colorectal cancer

Original Article

Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors

Original Article

Oral and intravenous pharmacokinetics of 5-fluoro-2′-deoxycytidine and THU in cynomolgus monkeys and humans
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits